Status:
COMPLETED
Efficacy and Safety of Ciclesonide Administered With or Without Different Spacers in Patients With Asthma (12 to 75 y) (BY9010/M1-145)
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
12-75 years
Phase:
PHASE3
Brief Summary
The aim of the present study is to investigate the efficacy and safety of ciclesonide on lung function and safety. Ciclesonide will be inhaled at one dose level once daily, using an inhaler device wit...
Eligibility Criteria
Inclusion
- Main
- Written informed consent
- History of persistent bronchial asthma for at least 6 months
- Good health with the exception of asthma
- Main
Exclusion
- Concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids
- Smoking history with ≥10 cigarette pack years
- Pregnancy
- Intention to become pregnant
- Breast feeding
- Lack of safe contraception
- Previous enrolment into the current study
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
End Date :
January 1 2006
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT00163436
Start Date
September 1 2005
End Date
January 1 2006
Last Update
November 30 2016
Active Locations (66)
Enter a location and click search to find clinical trials sorted by distance.
1
Altana Pharma/Nycomed
La Malbaie, Quebec, Canada, G5A 1W7
2
Altana Pharma/Nycomed
London, Canada, N6A 5R9
3
Altana Pharma/Nycomed
London,ON, Canada, N6A1V2
4
Altana Pharma/Nycomed
Mississauga, Canada, L5B 1N1